数千万融资！国产蛋白组学分析平台完成种子轮

Core Viewpoint - Shenzhen Zhaojixin Biotech Co., Ltd. has completed a seed round financing of several tens of millions, led by Shenzhen Capital Group, to advance its AI-driven high-throughput, ultra-sensitive protein analysis platform [1] Company Positioning - Founded in 2023, Zhaojixin is established by experts from various fields including biochip materials, semiconductor processes, computational optics, and life science instrumentation [1] - The company aims to build a next-generation ultra-sensitive protein detection platform, with a focus on developing dozens of patents around its core technology [1] - The technology has been validated to detect femtogram-level protein markers in blood samples, showcasing clear advantages in cost, stability, integration, and intelligence [1] Technology Integration - The core of Zhaojixin's technology system is the Integrated Surface Array Sensor (ISAS), which combines microfluidic droplets, on-chip imaging, and AI computational optics for ultra-sensitive detection [4] - ISAS utilizes semiconductor processes to embed fluorescence detection pathways directly into chips, transitioning biological detection devices into a scalable digital imaging era [5] - Advantages of ISAS include: - Large field of view and high integration, allowing linear expansion of detection capabilities with chip area [7] - Significant reduction in equipment cost and size compared to traditional microscopy [8] - Enhanced automation and controllability of imaging processes [9] - The ISAS technology supports not only protein detection but also potential extensions into cell analysis and spatial molecular imaging [10] Application Prospects - Zhaojixin's platform has clear application pathways in drug development and clinical diagnostics [16] - In drug development, the platform addresses structural needs for high sensitivity and consistency, particularly in neurodegenerative diseases, autoimmune diseases, and tumor immunotherapy [17] - The platform's capabilities position it as an integral tool in the entire drug development process [18] - In clinical diagnostics, the platform targets high-value disease areas, offering femtogram-level sensitivity, large-scale data acquisition, and cross-batch consistency [19][20] - The company is exploring applications in diseases that require high sensitivity, stability, and consistency, leveraging the advantages of the semiconductor and AI approach [21][24] Conclusion - The recent financing will accelerate Zhaojixin's advancements in foundational technology, algorithm systems, and industrialization pathways [22] - The integration of ISAS, microfluidic droplets, and AI computational optics aims to create a digital biological analysis infrastructure for future life sciences [22]